Evidence map›Paper›PMID 30327889›Full record

ArticleJournal of molecular modeling2018

Pharmacophore modeling, docking and molecular dynamics to identify Leishmania major farnesyl pyrophosphate synthase inhibitors.

Larissa de Mattos Oliveira, Janay Stefany Carneiro Araújo, David Bacelar Costa Junior, Isis Bugia Santana, Angelo Amâncio Duarte, Franco Henrique Andrade Leite, Raquel Guimarães Benevides, Manoelito Coelho Dos Santos Junior

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular modeling, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Research in pharmaceutical sciences · 2026
    Article
  2. Silver-Pharmaceuticals (Basel, Switzerland) · 2026
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Larissa de Mattos OliveiraPrograma de Pós-graduação em Ciências Farmacêuticas, Universidade Estadual de Feira de Santana, Feira de Santana, Brazil.
Janay Stefany Carneiro AraújoPrograma de Pós-graduação em Ciências Farmacêuticas, Universidade Estadual de Feira de Santana, Feira de Santana, Brazil.
David Bacelar Costa JuniorPrograma de Pós-graduação em Ciências Farmacêuticas, Universidade Estadual de Feira de Santana, Feira de Santana, Brazil.
Isis Bugia SantanaLaboratório de Modelagem Molecular, Departamento de Saúde, Universidade Estadual de Feira de Santana, Feira de Santana, Brazil.
Angelo Amâncio DuarteLaboratório de Computação de Alto Desempenho, Universidade Estadual de Feira de Santana, Feira de Santana, Brazil.
Franco Henrique Andrade LeitePrograma de Pós-graduação em Ciências Farmacêuticas, Universidade Estadual de Feira de Santana, Feira de Santana, Brazil.
Raquel Guimarães BenevidesPrograma de Pós-graduação em Biotecnologia, Universidade Estadual de Feira de Santana, Feira de Santana, Brazil.
Manoelito Coelho Dos Santos JuniorPrograma de Pós-graduação em Ciências Farmacêuticas, Universidade Estadual de Feira de Santana, Feira de Santana, Brazil. manoelito@uefs.com.br.ORCID http://orcid.org/0000-0002-3271-3529

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leishmaniasis is caused by protozoa of the genus Leishmania spp. and is considered the second most important protozoa in the world due to the number of cases and mortality. Despite its importance in terms of public health, the treatment of patients is limited and has mostly low levels of efficacy and safety. Farnesyl pyrophosphate synthase (FPPS) acts in the early stages of isoprenoid synthesis, and is important for maintaining the integrity of the lipid bilayer of the parasite that causes the disease. The aim of this work was to identify one potential inhibitor of the FPPS of Leishmania major through virtual screening by pharmacophore modeling and docking. A total of 85,000 compounds from a natural products database (ZINC

Indexed as

Drug DesignMolecular Docking SimulationMolecular Dynamics SimulationEnzyme InhibitorsGeranyltranstransferaseLeishmania majorLigandsEnzyme InhibitorsGeranyltranstransferaseLigandsFarnesyl pyrophosphate synthaseLeishmaniasisMolecular dynamicsVirtual screening

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.